Regulatory briefing

Our regulatory briefings section delivers current and up-to-date legal and regulatory news relating to all aspects of the CBD industry. It covers individual regulation changes across the world, policy and governmental changes that impact the industry and technological and medical innovations that affect how the industry is regulated, to name a few.

US states providing tax relief measures in midst of COVID-19

Written by CBD-Intel || 8th May 2020 || Regulatory briefing |

Alabama
California
Colorado
Connecticut
Iowa
Kentucky
Massachusetts
Michigan
New York
North America
North Carolina
Oregon
Pennsylvania
Tennessee
Texas
United States
Vermont
Washington
COVID-19
Regulation and Legislation
Regulatory briefing
Every state in the US is offering some sort of tax relief in response to the coronavirus pandemic, and many hemp and CBD companies may be eligible for such relief ...

Government shutdown delays next step towards Mexican legalisation

Written by CBD-Intel || 23rd April 2020 || Regulatory briefing |

Mexico
North America
COVID-19
Policy and Politics
Regulation and Legislation
Regulatory briefing
Further advances towards the legalisation of cannabis in Mexico have been delayed by a government shutdown due to the COVID-19 pandemic, with a new deadline for legislation set by the country’s Supreme Court ...

Divisions over drug policy lead to fresh delay in UN vote on restrictions

Written by CBD-Intel || 16th March 2020 || Regulatory briefing |

EU
Europe
Mexico
North America
Russia
South America
Switzerland
United Kingdom
United States
Uruguay
World
Policy and Politics
Regulation and Legislation
Regulatory briefing
The United Nations’ central drug policy agency has declined to reveal why it again postponed a vote on WHO recommendations to relax restrictions on cannabis and related substances such as CBD and THC ...

Law firm leads call for joined-up hemp regulation between US states

Written by CBD-Intel || 5th March 2020 || Regulatory briefing |

Canada
Colorado
New York
North America
United States
Companies
Policy and Politics
Regulation and Legislation
Regulatory briefing
A coalition of organisations linked to the US hemp market has released the first part of a series of policy recommendations – while one CBD firm has been referred to the US Federal Trade Commission over extravagant health...

Clarity needed over CBD pet and animal products in the US

Written by CBD-Intel || 25th February 2020 || Regulatory briefing |

North America
United States
Companies
Marketing and Retailing
Regulation and Legislation
Regulatory briefing
A lack of clear regulation has not stopped growth for companies looking at the US CBD pet and animal sector, but for the industry to see the niche truly embraced, some solution to the regulatory issues must first...

BfR issues warning over adulterated German e-liquids

Written by CBD-Intel || 21st February 2020 || Regulatory briefing |

Europe
Germany
Health
Policy and Politics
Regulation and Legislation
Regulatory briefing
Germany's Federal Institute for Risk Assessment (BfR) recently issued a warning on e-liquids that it believed to be containing synthetic cannabinoids, after at least eight teenagers suffered medical complications from an as yet unconfirmed source ...

Polish agricultural subcommittee meet to discuss hemp cultivation

Written by CBD-Intel || 20th February 2020 || Regulatory briefing |

Europe
Poland
Regulation and Legislation
Regulatory briefing
Polish lawmakers from the Permanent Subcommittee on Bioeconomy and Innovation in Agriculture at the Sejm – the lower chamber of the country’s parliament – recently hosted government officials, representatives of the Polish and the European hemp industry, and...

US Congress members bid again to make CBD supplements legal

Written by CBD-Intel || 29th January 2020 || Regulatory briefing |

North America
United States
Policy and Politics
Regulation and Legislation
US federal regulation
Regulatory briefing
Leading members of the US Congress are again pushing for the legalisation of dietary supplements containing hemp-derived CBD, currently banned by the Food and Drug Administration (FDA) ...